Gossamer Bio (GOSS) revenue and earnings history
Gossamer Bio reported revenue of $48.5M for fiscal 2025 (year ended Dec 31, 2025), −57.7% on the year before, and net income of −$170M.
Revenue and net income, 9 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $48.5M−57.7% | −$171M | −$170M | −$171M | $79K | −$171M | $10.6M | — | — | $37.7M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Gossamer Bio (GOSS) on OQRO.
Common questions
What was Gossamer Bio's revenue in fiscal 2025?
$48.5M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 17, 2026. That is −57.7% on fiscal 2024 ($115M).
Has Gossamer Bio been profitable?
It reported a net loss in 9 of the years shown (2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$6.77M in fiscal 2017.
What was Gossamer Bio's free cash flow in fiscal 2025?
−$171M: operating cash flow of −$171M minus capital expenditure of $79K. OQRO calculates free cash flow this way from the two filed lines.
Where these figures come from
The SEC’s companyfacts data: every figure Gossamer Bio tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
